WuXi Biologics (Cayman) Inc. released its May 2026 Monthly Return, showing only minor share count changes while maintaining full compliance with Hong Kong’s public-float rules.

Key figures

1. Issued share movements • 86,800 new ordinary shares were issued through the exercise of Pre-IPO share options, lifting the total outstanding shares to 4,140.91 million. • The month-on-month dilution was negligible at 0.002 percent. • Net proceeds from option exercises amounted to USD 0.02 million.

2. Share repurchases • 4.51 million shares were repurchased on 27–29 May 2026 but had not yet been cancelled by month-end. • The repurchased shares equal 0.11 percent of the current issued share base, more than offsetting the shares created via option exercises once cancellation is completed.

3. Capital structure and authorisation • Authorised capital remained unchanged at 6 billion ordinary shares with a par value of USD 1/120,000, translating to an authorised share capital of USD 50,000. • No treasury shares were held, issued, or cancelled during the period.

4. Equity incentive overhang • Outstanding Pre-IPO options total 28.83 million shares. • A further 98.50 million shares are reserved under the company’s Restricted Share Award Scheme and Global Partner Program.

5. Public-float status WuXi Biologics confirmed that it met the 15 percent minimum public-float requirement as of 31 May 2026.

The disclosure highlights disciplined capital management, with minimal dilution from option exercises and a continuing buyback programme poised to reduce the share count once cancellations are processed.